Protalix BioTherapeutics (PLX) Other Non-Current Assets (2010 - 2026)
Protalix BioTherapeutics' quarterly Other Non-Current Assets came in at $589000.0 in Q1 2026, up 28.32% year-on-year from $459000.0 in Q1 2025, and up 1.9% quarter-over-quarter from $578000.0 in Q4 2025.
Protalix BioTherapeutics has reported Other Non-Current Assets for 17 years, with the latest figure at $589000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 28.32% year-over-year to $589000.0; the trailing twelve-month figure through Mar 2026 stood at $589000.0 (up 28.32% YoY), and the FY2025 full-year result was $578000.0, up 25.11% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $589000.0, up from $578000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.1 million in Q1 2022, with the low at $459000.0 in Q1 2025.
- Average Other Non-Current Assets over 5 years is $896000.0, with a median of $578000.0 recorded in 2025.
- Year-over-year, Other Non-Current Assets slumped 58.33% in 2023 and grew 28.32% in 2026.
- Tracing PLX's Other Non-Current Assets over 5 years: stood at $1.3 million in 2022, then plunged by 58.33% to $528000.0 in 2023, then slipped by 12.5% to $462000.0 in 2024, then increased by 25.11% to $578000.0 in 2025, then climbed by 1.9% to $589000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $589000.0 (Q1 2026), $578000.0 (Q4 2025), and $549000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 589,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 549,000.00 |
| Jun 30, 2025 | 520,000.00 |
| Mar 31, 2025 | 459,000.00 |
| Dec 31, 2024 | 462,000.00 |
| Sep 30, 2024 | 561,000.00 |
| Jun 30, 2024 | 535,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 2.05 Mn |
| Dec 31, 2021 | 2.08 Mn |
| Sep 30, 2021 | 1.95 Mn |
| Jun 30, 2021 | 1.88 Mn |
| Mar 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 1.80 Mn |
| Sep 30, 2020 | 1.64 Mn |
| Jun 30, 2020 | 2.01 Mn |
| Mar 31, 2020 | 1.88 Mn |
| Dec 31, 2019 | 1.96 Mn |
| Sep 30, 2019 | 1.95 Mn |
| Jun 30, 2019 | 1.87 Mn |
| Mar 31, 2019 | 1.80 Mn |
| Dec 31, 2018 | 1.76 Mn |
| Sep 30, 2018 | 1.78 Mn |
| Jun 30, 2018 | 1.73 Mn |
| Mar 31, 2018 | 1.80 Mn |
| Dec 31, 2017 | 1.89 Mn |
| Sep 30, 2017 | 211,000.00 |
| Jun 30, 2017 | 1.95 Mn |
| Mar 31, 2017 | 205,000.00 |
| Dec 31, 2016 | 1.68 Mn |
| Sep 30, 2016 | 1.69 Mn |
| Jun 30, 2016 | 1.74 Mn |
| Mar 31, 2016 | 1.73 Mn |
| Dec 31, 2015 | 1.63 Mn |
| Dec 31, 2014 | 1.56 Mn |
| Mar 31, 2014 | 1.62 Mn |
| Dec 31, 2013 | 141,000.00 |
| Sep 30, 2013 | 1.47 Mn |
| Jun 30, 2013 | 1.37 Mn |
| Mar 31, 2013 | 1.34 Mn |
| Dec 31, 2012 | 1.25 Mn |
| Sep 30, 2012 | 1.13 Mn |
| Jun 30, 2012 | 1.07 Mn |
| Mar 31, 2012 | 1.12 Mn |
| Dec 31, 2011 | 1.04 Mn |
| Sep 30, 2011 | 2.04 Mn |
| Jun 30, 2011 | 1.75 Mn |
| Dec 31, 2010 | 942,000.00 |